Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Standard BioTools ( (LAB) ) has provided an update.
Standard BioTools Inc. held its 2025 Annual Meeting of Stockholders on June 18, 2025, where stockholders approved an amendment to the company’s Amended and Restated 2011 Equity Incentive Plan, increasing the number of shares of common stock reserved for issuance by 17,400,000 shares. Additionally, the election of Class III directors, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm were also confirmed during the meeting.
The most recent analyst rating on (LAB) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.
Spark’s Take on LAB Stock
According to Spark, TipRanks’ AI Analyst, LAB is a Neutral.
Standard BioTools’ overall stock score reflects significant financial challenges, with persistent losses and cash flow issues being major concerns. While the technical analysis indicates a neutral trend, the valuation metrics highlight current profitability issues. Positive aspects include strategic initiatives and improved financial discipline, as noted in the earnings call.
To see Spark’s full report on LAB stock, click here.
More about Standard BioTools
Average Trading Volume: 1,273,310
Technical Sentiment Signal: Sell
Current Market Cap: $414M
For a thorough assessment of LAB stock, go to TipRanks’ Stock Analysis page.